<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>JMG Contact blog</title>
	<atom:link href="http://blogs.bmj.com/jmg/feed/" rel="self" type="application/rss+xml" />
	<link>http://blogs.bmj.com/jmg</link>
	<description>JMG Contact blog</description>
	<lastBuildDate>Sat, 18 May 2013 06:18:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly</title>
		<link>http://blogs.bmj.com/jmg/2013/05/18/disruption-of-tbc1d7-a-subunit-of-the-tsc1-tsc2-protein-complex-in-intellectual-disability-and-megalencephaly/</link>
		<comments>http://blogs.bmj.com/jmg/2013/05/18/disruption-of-tbc1d7-a-subunit-of-the-tsc1-tsc2-protein-complex-in-intellectual-disability-and-megalencephaly/#comments</comments>
		<pubDate>Sat, 18 May 2013 06:18:06 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=534</guid>
		<description><![CDATA[Mutations in TSC1 or TSC2 cause Tuberous Sclerosis Complex (TSC) a multisystemic disorder with many features including intellectual disability (ID). TSC1, TSC2 and TBC1D7 form a complex that inhibits mTORC1 signaling and limits cell growth. Using homozygosity mapping and exome sequencing to study a consanguineous family with ID and megalencephaly, we identified, in the affected individuals, [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton534" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F18%2Fdisruption-of-tbc1d7-a-subunit-of-the-tsc1-tsc2-protein-complex-in-intellectual-disability-and-megalencephaly%2F&amp;via=JMedGeneticsBMJ&amp;text=Disruption%20of%20TBC1D7%2C%20a%20subunit%20of%20the%20TSC1-TSC2%20protein%20complex%2C%20in%20intellectual%20disability...%20&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F18%2Fdisruption-of-tbc1d7-a-subunit-of-the-tsc1-tsc2-protein-complex-in-intellectual-disability-and-megalencephaly%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Mutations in <i>TSC1</i> or <i>TSC2</i> cause Tuberous Sclerosis Complex (TSC) a multisystemic disorder with many features including intellectual disability (ID). TSC1, TSC2 and TBC1D7 form a complex that inhibits mTORC1 signaling and limits cell growth. Using homozygosity mapping and exome sequencing to study a consanguineous family with ID and megalencephaly, we identified, in the affected individuals, a homozygous truncating mutation in <i>TBC1D7</i>. This mutation (p.Y180fsX1) abolishes TBC1D7 expression and is associated with increased mTORC1 signaling in cells of the affected individuals. Our study shows that disruption of TBC1D7 causes ID but without the other typical features found in TSC. (By Fadi F. Hamdan, PhD, <a href="http://jmg.bmj.com/content/early/2013/05/16/jmedgenet-2013-101680">http://jmg.bmj.com/content/early/2013/05/16/jmedgenet-2013-101680</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/05/18/disruption-of-tbc1d7-a-subunit-of-the-tsc1-tsc2-protein-complex-in-intellectual-disability-and-megalencephaly/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Loss of function of the E3 ubiquitin-protein ligase UBE3B causes Kaufman oculocerebrofacial syndrome</title>
		<link>http://blogs.bmj.com/jmg/2013/05/18/loss-of-function-of-the-e3-ubiquitin-protein-ligase-ube3b-causes-kaufman-oculocerebrofacial-syndrome/</link>
		<comments>http://blogs.bmj.com/jmg/2013/05/18/loss-of-function-of-the-e3-ubiquitin-protein-ligase-ube3b-causes-kaufman-oculocerebrofacial-syndrome/#comments</comments>
		<pubDate>Sat, 18 May 2013 06:15:46 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=531</guid>
		<description><![CDATA[Kaufman oculocerebrofacial syndrome (KOS) is a rare disorder affecting development and growth originally recognized 40 years ago. KOS is characterised by microcephaly, mental retardation, ocular anomalies, distinctive facial features, generalised hypotonia, and reduced growth. In this paper, exome sequencing was employed to identify UBE3B, encoding an E3 ubiquitin-protein ligase, as the gene mutated in KOS. [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton531" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F18%2Floss-of-function-of-the-e3-ubiquitin-protein-ligase-ube3b-causes-kaufman-oculocerebrofacial-syndrome%2F&amp;via=JMedGeneticsBMJ&amp;text=Loss%20of%20function%20of%20the%20E3%20ubiquitin-protein%20ligase%20UBE3B%20causes%20Kaufman%20oculocerebrofacial...%20&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F18%2Floss-of-function-of-the-e3-ubiquitin-protein-ligase-ube3b-causes-kaufman-oculocerebrofacial-syndrome%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Kaufman oculocerebrofacial syndrome (KOS) is a rare disorder affecting development and growth originally recognized 40 years ago. KOS is characterised by microcephaly, mental retardation, ocular anomalies, distinctive facial features, generalised hypotonia, and reduced growth. In this paper, exome sequencing was employed to identify <i>UBE3B</i>, encoding an E3 ubiquitin-protein ligase, as the gene mutated in KOS. Molecular data demonstrate that this disorder is a clinically homogeneous, recessive trait caused by UBE3B loss of function. This finding further demonstrates the impact of misregulation of protein ubiquitination on development and growth. (By Marco Tartaglia, PhD, <a href="http://jmg.bmj.com/content/early/2013/05/16/jmedgenet-2012-101405">http://jmg.bmj.com/content/early/2013/05/16/jmedgenet-2012-101405</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/05/18/loss-of-function-of-the-e3-ubiquitin-protein-ligase-ube3b-causes-kaufman-oculocerebrofacial-syndrome/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An X chromosome-wide association analysis identifies variants in GPR174 as a risk factor to Graves’ disease</title>
		<link>http://blogs.bmj.com/jmg/2013/05/10/an-x-chromosome-wide-association-analysis-identifies-variants-in-gpr174-as-a-risk-factor-to-graves-disease/</link>
		<comments>http://blogs.bmj.com/jmg/2013/05/10/an-x-chromosome-wide-association-analysis-identifies-variants-in-gpr174-as-a-risk-factor-to-graves-disease/#comments</comments>
		<pubDate>Fri, 10 May 2013 20:46:01 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=529</guid>
		<description><![CDATA[Graves’ disease is an autoimmune illness mostly seen in female. The contribution of the X chromosomes to its risk has long been appreciated. We re-examined the X chromosome data from our recent study using a technology named genome-wide association study (GWAS). A single nucleotide polymorphism (SNP) which changes an amino acid within the G protein-coupled [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton529" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F10%2Fan-x-chromosome-wide-association-analysis-identifies-variants-in-gpr174-as-a-risk-factor-to-graves-disease%2F&amp;via=JMedGeneticsBMJ&amp;text=An%20X%20chromosome-wide%20association%20analysis%20identifies%20variants%20in%20GPR174%20as%20a%20risk%20factor%20to...%20&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F10%2Fan-x-chromosome-wide-association-analysis-identifies-variants-in-gpr174-as-a-risk-factor-to-graves-disease%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Graves’ disease is an autoimmune illness mostly seen in female. The contribution of the X chromosomes to its risk has long been appreciated. We re-examined the X chromosome data from our recent study using a technology named genome-wide association study (GWAS). A single nucleotide polymorphism (SNP) which changes an amino acid within the G protein-coupled receptor 174 gene (<i>GPR174</i>)  on Xq21.1, namely rs3827440, was associated with susceptibility to Graves’ disease and the odds ratio was next to that of the <i>HLA</i> SNPs, the previously established most significant locus related to this disease. Resequencing results revealed other rare variants of <i>GPR174</i> also contributed to disease risk. <i>GPR174 </i>is widely expressed in immune-related tissues and might serve as a potential drug target in future studies. The finding of an X-linked risk locus for Graves’ disease expands our understanding of the role played by X chromosome in the pathogenesis of autoimmune diseases. (Professor Wei Huang, <a href="http://jmg.bmj.com/content/early/2013/05/09/jmedgenet-2013-101595">http://jmg.bmj.com/content/early/2013/05/09/jmedgenet-2013-101595</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/05/10/an-x-chromosome-wide-association-analysis-identifies-variants-in-gpr174-as-a-risk-factor-to-graves-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Upregulation of RCAN1 causes Down syndrome-like immune dysfunction</title>
		<link>http://blogs.bmj.com/jmg/2013/05/03/upregulation-of-rcan1-causes-down-syndrome-like-immune-dysfunction/</link>
		<comments>http://blogs.bmj.com/jmg/2013/05/03/upregulation-of-rcan1-causes-down-syndrome-like-immune-dysfunction/#comments</comments>
		<pubDate>Fri, 03 May 2013 19:39:44 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=527</guid>
		<description><![CDATA[People with Down syndrome (DS) (trisomy 21) have impaired immune function making them susceptible to infections and autoimmune disease. The molecular cause for this impairment is undetermined. Using mice we have found that an excess of RCAN1, a protein expressed at higher than normal levels in DS, adversely affects key immune functions, and that an [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton527" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F03%2Fupregulation-of-rcan1-causes-down-syndrome-like-immune-dysfunction%2F&amp;via=JMedGeneticsBMJ&amp;text=Upregulation%20of%20RCAN1%20causes%20Down%20syndrome-like%20immune%20dysfunction&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F05%2F03%2Fupregulation-of-rcan1-causes-down-syndrome-like-immune-dysfunction%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>People with Down syndrome (DS) (trisomy 21) have impaired immune function making them susceptible to infections and autoimmune disease. The molecular cause for this impairment is undetermined. Using mice we have found that an excess of RCAN1, a protein expressed at higher than normal levels in DS, adversely affects key immune functions, and that an excess of RCAN1 leads to suppression of the immune system. Our findings are of clinical relevance to DS and may also find application in situations in the non-DS population where suppression of the immune system is desirable; for example, in autoimmune disease or graft versus host responses. (By Dr. Melanie Pritchard, <a href="http://jmg.bmj.com/content/early/2013/05/02/jmedgenet-2013-101522">http://jmg.bmj.com/content/early/2013/05/02/jmedgenet-2013-101522</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/05/03/upregulation-of-rcan1-causes-down-syndrome-like-immune-dysfunction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mutation in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual disability and strabismus</title>
		<link>http://blogs.bmj.com/jmg/2013/04/26/mutation-in-adat3-encoding-adenosine-deaminase-acting-on-transfer-rna-causes-intellectual-disability-and-strabismus/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/26/mutation-in-adat3-encoding-adenosine-deaminase-acting-on-transfer-rna-causes-intellectual-disability-and-strabismus/#comments</comments>
		<pubDate>Fri, 26 Apr 2013 03:23:00 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=525</guid>
		<description><![CDATA[Intellectual disability (ID) is one of the most common disabilities worldwide, affecting nearly 2% of the global population. Here we examined patients from eight families suffering from a form of ID that is coupled with squint of the eye, and in each case found the same DNA mutation, in a gene called ADAT3. This gene [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton525" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F26%2Fmutation-in-adat3-encoding-adenosine-deaminase-acting-on-transfer-rna-causes-intellectual-disability-and-strabismus%2F&amp;via=JMedGeneticsBMJ&amp;text=Mutation%20in%20ADAT3%2C%20encoding%20adenosine%20deaminase%20acting%20on%20transfer%20RNA%2C%20causes%20intellectual...%20&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F26%2Fmutation-in-adat3-encoding-adenosine-deaminase-acting-on-transfer-rna-causes-intellectual-disability-and-strabismus%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Intellectual disability (ID) is one of the most common disabilities worldwide, affecting nearly 2% of the global population. Here we examined patients from eight families suffering from a form of ID that is coupled with squint of the eye, and in each case found the same DNA mutation, in a gene called ADAT3. This gene is part of a sub-machinery vital for correctly converting DNA into protein within the cell, and excitingly this is the first time that a human mutation has been uncovered in this particular sub-machinery. Although mutations in a large number of genes lead to general ID, focusing on ID that contains a second defining feature (in this case, squint) appears to result in more focused genetic findings. (By Dr. Fowzan S Alkuraya, <a href="http://jmg.bmj.com/content/early/2013/04/24/jmedgenet-2012-101378">http://jmg.bmj.com/content/early/2013/04/24/jmedgenet-2012-101378</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/26/mutation-in-adat3-encoding-adenosine-deaminase-acting-on-transfer-rna-causes-intellectual-disability-and-strabismus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A novel syndrome of hypohidrosis and intellectual disability is linked to COG6 deficiency</title>
		<link>http://blogs.bmj.com/jmg/2013/04/20/a-novel-syndrome-of-hypohidrosis-and-intellectual-disability-is-linked-to-cog6-deficiency/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/20/a-novel-syndrome-of-hypohidrosis-and-intellectual-disability-is-linked-to-cog6-deficiency/#comments</comments>
		<pubDate>Sat, 20 Apr 2013 18:23:51 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=523</guid>
		<description><![CDATA[Intellectual disability (ID) is a common disability in humans and comprises both isolated forms as well as forms that are associated with a constellation of other clinical problems i.e. syndromic ID.  In this study, we describe an apparently novel syndromic ID in which patients have decreased sweating and brittle teeth.  Using positional cloning techniques in [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton523" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F20%2Fa-novel-syndrome-of-hypohidrosis-and-intellectual-disability-is-linked-to-cog6-deficiency%2F&amp;via=JMedGeneticsBMJ&amp;text=A%20novel%20syndrome%20of%20hypohidrosis%20and%20intellectual%20disability%20is%20linked%20to%20COG6%20deficiency&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F20%2Fa-novel-syndrome-of-hypohidrosis-and-intellectual-disability-is-linked-to-cog6-deficiency%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Intellectual disability (ID) is a common disability in humans and comprises both isolated forms as well as forms that are associated with a constellation of other clinical problems i.e. syndromic ID.  In this study, we describe an apparently novel syndromic ID in which patients have decreased sweating and brittle teeth.  Using positional cloning techniques in combination with next-generation sequencing, we identified a mutation in COG6 as the likely cause.  Interestingly, a previous report described a mutation in COG6 in a patient with congenital disorder of glycosylation, something we did not observe in the patients in this study.  Additional COG6 mutations are needed to establish the exact phenotype associated with COG6 deficiency in humans. (By Dr Fowzan S Alkuraya, <a href="http://jmg.bmj.com/content/early/2013/04/19/jmedgenet-2013-101527">http://jmg.bmj.com/content/early/2013/04/19/jmedgenet-2013-101527</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/20/a-novel-syndrome-of-hypohidrosis-and-intellectual-disability-is-linked-to-cog6-deficiency/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A new gene for childhood-onset pulmonary arterial hypertension</title>
		<link>http://blogs.bmj.com/jmg/2013/04/16/a-new-gene-for-childhood-onset-pulmonary-arterial-hypertension/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/16/a-new-gene-for-childhood-onset-pulmonary-arterial-hypertension/#comments</comments>
		<pubDate>Tue, 16 Apr 2013 19:05:51 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=521</guid>
		<description><![CDATA[Pulmonary arterial hypertension (PAH) in children is a progressive and often fatal disease of the lung vessels, for which no curative therapy exists. PAH may be heritable: mutations in the BMPR2-gene have been found in about 15% of children with the disease. In a national cohort of Dutch children with unexplained PAH, we identified mutations [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton521" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F16%2Fa-new-gene-for-childhood-onset-pulmonary-arterial-hypertension%2F&amp;via=JMedGeneticsBMJ&amp;text=A%20new%20gene%20for%20childhood-onset%20pulmonary%20arterial%20hypertension&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F16%2Fa-new-gene-for-childhood-onset-pulmonary-arterial-hypertension%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Pulmonary arterial hypertension (PAH) in children is a progressive and often fatal disease of the lung vessels, for which no curative therapy exists. PAH may be heritable: mutations in the BMPR2-gene have been found in about 15% of children with the disease. In a national cohort of Dutch children with unexplained PAH, we identified mutations of the TBX4-gene in 30% of the cases. TBX4-mutations have previously been shown to cause Small Patella Syndrome (SPS) and, interestingly, the pediatric PAH-patients with TBX4 mutations, also appeared to have SPS. This is the first time that TBX4-mutations are reported in PAH. (By Dr. Wilhelmina S Kerstjens-Frederikse, <a href="http://jmg.bmj.com/content/early/2013/04/15/jmedgenet-2012-101152">http://jmg.bmj.com/content/early/2013/04/15/jmedgenet-2012-101152</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/16/a-new-gene-for-childhood-onset-pulmonary-arterial-hypertension/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations</title>
		<link>http://blogs.bmj.com/jmg/2013/04/09/troponin-activator-augments-muscle-force-in-nemaline-myopathy-patients-with-nebulin-mutations/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/09/troponin-activator-augments-muscle-force-in-nemaline-myopathy-patients-with-nebulin-mutations/#comments</comments>
		<pubDate>Tue, 09 Apr 2013 18:34:06 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=519</guid>
		<description><![CDATA[Nemaline myopathy (NM) is the most common non-dystrophic congenital myopathy and is most frequently caused by mutations in the nebulin gene. The sarcomeric protein nebulin plays a crucial role in skeletal muscle performance. NM patients with nebulin mutations have muscle weakness through mechanisms including a lower responsiveness to calcium. No therapy exists to treat muscle [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton519" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Ftroponin-activator-augments-muscle-force-in-nemaline-myopathy-patients-with-nebulin-mutations%2F&amp;via=JMedGeneticsBMJ&amp;text=Troponin%20activator%20augments%20muscle%20force%20in%20nemaline%20myopathy%20patients%20with%20nebulin%20mutations&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Ftroponin-activator-augments-muscle-force-in-nemaline-myopathy-patients-with-nebulin-mutations%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Nemaline myopathy (NM) is the most common non-dystrophic congenital myopathy and is most frequently caused by mutations in the nebulin gene. The sarcomeric protein nebulin plays a crucial role in skeletal muscle performance. NM patients with nebulin mutations have muscle weakness through mechanisms including a lower responsiveness to calcium. No therapy exists to treat muscle weakness in NM. Here, we show that the novel fast skeletal muscle troponin activator, CK-2066260, augments force generation at submaximal calcium levels &#8211; levels that are typically used for daily life activities. Thus, fast troponin activation is a therapeutic mechanism to augment muscle strength in NM patients with nebulin mutations. (By Dr. Josine de Winter, <a href="http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2012-101470">http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2012-101470</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/09/troponin-activator-augments-muscle-force-in-nemaline-myopathy-patients-with-nebulin-mutations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rhizomelic chondrodysplasia punctata and cardiac pathology</title>
		<link>http://blogs.bmj.com/jmg/2013/04/09/rhizomelic-chondrodysplasia-punctata-and-cardiac-pathology/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/09/rhizomelic-chondrodysplasia-punctata-and-cardiac-pathology/#comments</comments>
		<pubDate>Tue, 09 Apr 2013 18:32:11 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=517</guid>
		<description><![CDATA[Rhizomelic Chondrodysplasia Punctata (RCDP) is a rare genetic disorder associated with symmetrical shortening of the upper arms and legs, contractures, cataracts and developmenatal delay. The levels of plasmalogens (major constituents of cellular membranes) are low. Although high levels of plasmalogens are normally found in the heart, heart abnormalities have not previously been strongly associated with [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton517" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Frhizomelic-chondrodysplasia-punctata-and-cardiac-pathology%2F&amp;via=JMedGeneticsBMJ&amp;text=Rhizomelic%20chondrodysplasia%20punctata%20and%20cardiac%20pathology&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Frhizomelic-chondrodysplasia-punctata-and-cardiac-pathology%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>Rhizomelic Chondrodysplasia Punctata (RCDP) is a rare genetic disorder associated with symmetrical shortening of the upper arms and legs, contractures, cataracts and developmenatal delay. The levels of plasmalogens (major constituents of cellular membranes) are low. Although high levels of plasmalogens are normally found in the heart, heart abnormalities have not previously been strongly associated with RCDP.  We found cardiac defects in 12/18(52%) RCDP patients, which is much higher than among the normal population. All 12 had type 1 RCDP, 11(92%) had the <i>PEX 7</i>:c.875T&gt;A mutation and their plasmalogen levels were very low. The cardiac lesions included holes in the heart, persistent ductus arteriosus, underdeveloped lung arteries, Tetrology of Fallot and valve abnormalities. Routine cardiac evaluation in the management of RCDP patients is thus advisable.  (By Drs. Sally-Ann Clur and Irene Huffnagel,<b> </b><a href="http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2013-101536">http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2013-101536</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/09/rhizomelic-chondrodysplasia-punctata-and-cardiac-pathology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Meta-Analysis of Genome-Wide Studies Identifies MEF2C SNPs Associated with Bone Mineral Density at Forearm</title>
		<link>http://blogs.bmj.com/jmg/2013/04/09/meta-analysis-of-genome-wide-studies-identifies-mef2c-snps-associated-with-bone-mineral-density-at-forearm/</link>
		<comments>http://blogs.bmj.com/jmg/2013/04/09/meta-analysis-of-genome-wide-studies-identifies-mef2c-snps-associated-with-bone-mineral-density-at-forearm/#comments</comments>
		<pubDate>Tue, 09 Apr 2013 18:30:27 +0000</pubDate>
		<dc:creator>hqqu</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://blogs.bmj.com/jmg/?p=514</guid>
		<description><![CDATA[This paper finds different variants in MEF2C are associated with forearm bone mineral density (BMD) compared to the MEF2C variants associated with femoral neck BMD. We conclude that these variants are likely independent signals that have different independent effects on the two BMD phenotypes. It is also possible that both associations arise from several rare [...]]]></description>
				<content:encoded><![CDATA[<div id="tweetbutton514" class="tw_button" style="float:right;margin-left:10px;"><a href="http://twitter.com/share?url=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Fmeta-analysis-of-genome-wide-studies-identifies-mef2c-snps-associated-with-bone-mineral-density-at-forearm%2F&amp;via=JMedGeneticsBMJ&amp;text=Meta-Analysis%20of%20Genome-Wide%20Studies%20Identifies%20MEF2C%20SNPs%20Associated%20with%20Bone%20Mineral%20Density...%20&amp;related=JMedGeneticsBMJ&amp;lang=en&amp;count=horizontal&amp;counturl=http%3A%2F%2Fblogs.bmj.com%2Fjmg%2F2013%2F04%2F09%2Fmeta-analysis-of-genome-wide-studies-identifies-mef2c-snps-associated-with-bone-mineral-density-at-forearm%2F" class="twitter-share-button"  style="width:55px;height:22px;background:transparent url('http://blogs.bmj.com/jmg/wp-content/plugins/wp-tweet-button/tweetn.png') no-repeat  0 0;text-align:left;text-indent:-9999px;display:block;"></a></div><p>This paper finds different variants in<i> MEF2C</i> are associated with forearm bone mineral density (BMD) compared to the<i> MEF2C</i> variants associated with femoral neck BMD. We conclude that these variants are likely independent signals that have different independent effects on the two BMD phenotypes. It is also possible that both associations arise from several rare causal variants on the same haplotype background. These results might suggest that the variants identified by GWAS are not causal, but the synthetic association created by rare variants with big effect size, however, this hypothesis will likely be tested as more sequencing studies emerge for BMD. (By Dr. Hou-Feng Zheng, <a href="http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2012-101287">http://jmg.bmj.com/content/early/2013/04/08/jmedgenet-2012-101287</a> )</p>
]]></content:encoded>
			<wfw:commentRss>http://blogs.bmj.com/jmg/2013/04/09/meta-analysis-of-genome-wide-studies-identifies-mef2c-snps-associated-with-bone-mineral-density-at-forearm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
